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Background: Continuous Glucose Monitoring (CGM) has become an increasingly
investigated tool, especially with regards to monitoring of diabetic and critical care
patients. The continuous glucose data allows the calculation of several glucose
variability parameters, however, without specific application the interpretation of the
results is time-consuming, utilizing extreme efforts. Our aim was to create an open
access software [Glycemic Variability Analyzer Program (GVAP)], readily available to
calculate the most common parameters of the glucose variability and to test its us-
ability.
Methods: The GVAP was developed in MATLAB® 2010b environment. The calculated
parameters were the following: average area above/below the target range (Avg.
AUC-H/L); Percentage Spent Above/Below the Target Range (PATR/PBTR); Continuous
Overall Net Glycemic Action (CONGA); Mean of Daily Differences (MODD); Mean
Amplitude of Glycemic Excursions (MAGE). For verification purposes we selected 14
CGM curves of pediatric critical care patients. Medtronic® Guardian® Real-Time with
Enlite® sensor was used. The reference values were obtained from Medtronic®’s own
software for Avg. AUC-H/L and PATR/PBTR, from GlyCulator for MODD and CONGA,
and using manual calculation for MAGE.
Results: The Pearson and Spearman correlation coefficients were above 0.99 for all
parameters. The initial execution took 30 minutes, for further analysis with the
Windows® Standalone Application approximately 1 minute was needed.
Conclusions: The GVAP is a reliable open access program for analyzing different
glycemic variability parameters, hence it could be a useful tool for the study of
glycemic control among critically ill patients.
Keywords: Glucose variability, Glucose homeostasis, Continuous glucose monitoring,
Critical care© 2015 Marics et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Marics et al. BioMedical Engineering OnLine  (2015) 14:37 Page 2 of 13Background
Continuous glucose monitoring (CGM) is primarily applied in diabetes care for both
clinical investigations and decision making. There are several promising studies sug-
gesting that CGM could be a useful method for monitoring of critically ill patients
[1-5]. However, the current guideline does not recommend CGM-based therapeutic de-
cisions under intensive care circumstances without surveillance. This guideline also ad-
vocates further investigations about the reliability of CGM devices in clinical settings
[6]. The final goal of monitoring glucose changes in critically ill patients is to maintain
blood glucose levels within a narrow range, i.e. avoiding fluctuations of glycemia. This
goal could be achieved in many cases by insulin therapy, or even by cortisone supple-
mentation. Intensive care glucose changes are resultant of multiple interactions of
glucose load, insulin secretion, and stress conditions mediated by cortisone or catechol-
amine secretion or autonomic nervous system activity. There are several models to de-
scribe glucose-insulin interaction taking into account many factors such as insulin
sensitivity, insulin clearance, endogenous glucose production etc. Common feature of
all the insulin-glucose models from the minimal model [7] through the pharmacoki-
netic model [8] to the most complex Sorensen model [9] is the consideration of glucose
concentrations in the interstitial compartment, being the interstitial fluid the field of
cellular insulin action. In the process of developing an appropriate algorithm for glu-
cose regulation in the intensive care unit, the variability of interstitial glucose changes
could not be neglected.
Applying CGM devices in the clinical practice or research needs appropriate, goal
oriented data handling methods. For instance Medtronic® CGM device can be evaluated
by a Windows- or Web-based program (Medtronic® CareLink® Professional/Personal),
which are widely used applications by physicians and diabetic patients. The main ad-
vantage of the above programs is that they provide clinically important graphical re-
ports, trends, areas and different parameters of glucose homeostasis with individually
adjustable threshold values. Reports contain, however, limited information as far as gly-
cemic variability is concerned; most accepted parameters, such as Mean of Daily Differ-
ences (MODD), Mean Amplitude of Glycemic Excursions (MAGE) and Continuous
Overall Net Glycemic Action (CONGA) are not available, raising an issue for re-
searchers. Raw data can be retrieved from both Medtronic® CareLink® Professional and
Personal, thus separate calculation of these parameters is possible. Recently, softwares
have been developed and found useful for the calculation of glycemic variability. The
GlyCulator is an application designed for the evaluation of glycemic variability based
on data collected by means of a CGM device and the program has been made access-
ible in a web-based, interface independent version [10]. Unfortunately, in this tool glu-
cose thresholds are not adjustable representing a disadvantage for research purposes.
Another application called CGM-GUIDE© (Continuous Glucose Monitoring-Graphical
User Interface for Diabetes Evaluation) calculates the most extensively used glucose
homeostasis parameters and variability metrics, exported from the CGM device in a
standard Excel data format [11]. It provides a user-friendly graphical interface, but it is
not widely available.
Recent studies suggested a linkage between glycemic variability and critical care mor-
tality. Elevated MAGE and standard deviation (SD) were found to be associated with
increased in-hospital mortality [12]. Signal et al. demonstrated that the odds of living
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range of 72–126 mg/dL [13]. On the basis of the above observations we carried out a
clinical study at a pediatric intensive care unit (PICU) setting with the aim to investi-
gate glycemic variability. For this purpose our team designed a CGM data handling and
analyzer program called Glycemic Variability Analyzer Program (GVAP). In this study
we evaluated the reliability of GVAP, compared to reference values and determined the
applicability of the software based on its user documentation. In the near future we will
make the software available for open access usage, with the advantages of open access
source code, adjustable thresholds and graphical user interface.Methods
CGM system
Interstitial glucose level was monitored by Guardian® REAL-Time (Medtronic®, USA)
CGM. The flexible platinum Enlite® sensor was inserted in the subcutaneous tissue of the
left or right lateral thigh and covered by transparent dressing. The calibration protocol
can be found in our previous publication [14]. The study was approved by the Research
Ethical Committee (number: TUKEB 2012/4) of the Semmelweis University, Budapest.Developmental model and software testing
Our applied software designed for special application has several different outputs and
mathematical algorithms as for certain data source. For the purposes of the develop-
ment, incremental method was applied and each algorithm was written and tested in
decomposed way. Following the algorithm design the next step involved the program-
ming environment selection. Our choice was influenced by the main task being rather
mathematical, therefore special software package application seemed to be optimal. Ac-
cordingly, MATLAB® (MathWorks®, USA) software was chosen. The GVAP program
was tested in three consecutive steps: during the (1) static test an expert programmer
read the source code row by row; (2) dynamic test addressed the evaluated data and al-
gorithm precision during process, throughout this step the source code was considered
as a black-box; (3) verification.Algorithm
In this application the main input was data on glucose concentration. The data chart
contained a sequential series of glucose concentrations at 5 minute intervals. Taking
into consideration the occasionally missing values, (e.g. secondary to late calibration) a
calculation of the missing data with linear interpolation was incorporated into the ini-
tial steps, when applicable. During the processing the following parameters were calcu-
lated based on their formulas (Table 1): Average area above/below the target range
(Avg. AUC-H/L); Percentage spent Above/Below the Target Range (PATR/PBTR);
CONGA; MODD; MAGE; Excursion Frequency (EF).
Within the whole programming process, the formulation of MAGE was found to be
the biggest challenge. Previously published algorithms were studied [15,16] and one of
them (Baghurst’s algorithm, Approach 1) was opted for use with minor modifications.
The MAGE algorithm embraced three main steps. The first element was the identifica-
tion of the turning points of the glucose data. Then, the turning points that were
Table 1 Definition of the calculated parameters of the GVAP
Name Formula Symbols
Avg. AUC-H 1T
Z T
0
G tð Þ−TRHð Þdt; IF G tð Þ > TRH
G (t) - Glucose–time function
Target Range-High - TRH
Avg. AUC-H - Average exposure to hyperglycemia.
Avg. AUC-H = 10 mg/dL means that during the
observation, on average the CGM glucose exceeded
TRH limit by 10 mg/dL [23].
Avg. AUC-L 1T
Z T
0
TRL−G tð Þð Þdt; IF G tð Þ < TRL
G (t) Glucose - time function
Target Range-Low - TRL
MAGE +/−
P λ
n IF λ > v
λ = amplitude of each glucose increase or decrease
(nadir to peak / peak to nadir)
n = number of observations
ν = meaningful excursion (ME)MAGE avg.
EF
MAGE+/−: mean of the upward/downward excursions
MAGE avg.: average of MAGEs
EF sum of all excursions [15,24,16]
MODD
Xtk
t¼t1 BGt−BGt−1440j j
k
BG: Blood Glucose
k = number of observations where there is an
observation at the same time 24 h (1,440 min)
ago [25,26]
CONGA (n)
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃPtk
t¼t1 Dt−
Dð Þ2
k−1
r
k = number of observations where there is an
observation n × 60 min ago
where Dt = BGt-BGt-m and
m = n × 60, in our program n = 1 [27,26]
D ¼
Ptk
t¼t1Dt
k
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adjacent maxima/minima were lower/higher (‘W’ and ‘M’ pattern) on both sides, were
retained. The third step comprised of the deletion of the turning points with countable
excursions on only one side. While keeping the backbone of the Baghurst’s algorithm
[15] two modifications were applied in our study design, as follows. In some cases, tak-
ing the first point of the glucose data as reference, the program could not identify a
meaningful excursion (ME), although the data set itself contained MEs. For this context
the program identified a new starting point. Moreover, when the program recognized
the first ME, it rechecked the glucose curve whether within the starting point and the
first identified ME any MEs were missed (Figure 1). The second modification affected
the turning points. Our algorithm retained the “W” and “M” patterns throughout the
calculation in contrary to the original method, which deleted them during the second
step. As a result of retaining certain turning points, the theoretical situation could arise,
when the final “MAGE” curve contained excursions below the threshold of ME. For
this latter scenario the program was designed to alert the users as follows, “Visual ana-
lysis should be performed, see User Documentation”. It should be noted, though that
this scenario occurred only in test circumstances. Figure 2 shows the entire algorithm
and Figure 3 presents the control panel of the GVAP.
Validation of the program
For validation of the program we used 14 CGM curves of clinical patients, and further
6 self-edited curves were evaluated for MAGE control with the aim to analyze extreme
Figure 1 An example of a CGM curve with its MAGE curve. A represents a CGM curve. In some cases from
the first glucose concentration (G (t1)) both the glucose maximum (G (t) MAX) and the minimum glucose
values (G (t) MIN) did not exceed the meaningful excursion (ME = 45 mg/dL) [G (t) MAX - G (t1) and
G (t1)-G (t) MIN≤ME], however, the entire curve contained MEs. On these occasions the program set the
new starting point - in this case G (t) MAX. B shows the MAGE curve.
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of Pediatrics, Semmelweis University, Budapest, between 2011 February and 2013
December. Our study was approved by the local research ethical committee. The CGM
data were collected by CareLink® Professional/Personal software in .xls file format. For
Figure 2 The algorithm. A and B show the entire algorithm of the Glycemic Variability Analyzer Program.
The MAGE algorithm was evolved based on a previous report by Baghurst et al. [15].
Marics et al. BioMedical Engineering OnLine  (2015) 14:37 Page 6 of 13the analysis 48-hour long periods were selected, where the Avg. AUC-H and/or the
Avg. AUC-L was > 0. Missing data was not an exclusion criterion, data interpolation
was permitted.
Glucose variability parameters calculated by our software were compared with the re-
sults of validated programs: 1. CareLink® Professional/Personal (Avg. AUC-H/L, PATR,
PBTR), 2. GlyCulator (CONGA, MODD). For MAGE (MAGE avg.) calculation manual
method was applied, as reference. Manual calculation followed the definition of MAGE
by Peter Baghurst [15]. In our study instead of standard deviation (SD) of the sample
we counted excursions exceeding 45 mg/dL in both directions. However, GVAP can
calculate the SD of the glucose data as well, and the user can overwrite the default
value of ME (45 mg/dL) when required for certain research purposes.
Statistical analysis
The accuracy of the GVAP was evaluated by using correlation and Bland-Altman ana-
lysis, Pearson or Spearman correlation, as appropriate. Statistical analysis was carried
out by SPSS® 13.0 software (SPSS® Inc., Chicago, IL, USA) and Microsoft® Excel 2010.
User documentation
In addition to the source code we also provided a brief user documentation (Additional
files 1 and 2), which had been tested by two independent users (DZ, CsH) without any
knowledge of the GVAP or MATLAB®.
Figure 3 The control panel of the program. The control panel allows the users to set the required target
range and meaningful excursions. The coherent results are in separate boxes. The user documentation
provides more details.
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CGM system
An average of 3.3 calibrations per 24 hours (range: 2–6) were performed in the selected
48-hour long periods. At the implantation site of the platinum sensor no undesirable
events (bleeding, irritation, decubitus and infection) occurred.
Verification of the program
Among the 14 patients 7 had missing data. The average amount of missing data per
24-hour recordings was 1.9 (range: 0–9), and glucose flow contained 286.1 (range:
279–288) points daily, on average. Correlation analysis between GVAP and validated
programs was performed. Pearson analysis (MAGE avg.), Pearson analysis after loga-
rithmic transformation (Avg. AUC-H, PATR) and Spearman analysis (Avg. AUC-L,
PBTR) were applied. Correlation coefficient was above 0.99 for all measured parameters
(Table 2). Compatibility of the methods was investigated by Bland-Altman analysis that
found outliers (above 2 SD) for 5 variables (Table 3, Figure 4).
User documentation
Taking into account the feedback from the examiners the user documentation was ad-
equately edited. Without any previous MATLAB experience the initial executions of
the program lasted approximately 30 minutes. The duration of further examinations
carried out with the Windows® Standalone Application was 1 minute, on average. The
most frequent practical default was identified as typing mismatch, when selecting the
excel-file to run the analysis.
Clinical implementation
For clinical consideration we demonstrate two CGM curves from a patient with severe
symptomatic hypoglycemia (glucose < 40 mg/dL) due to dumping syndrome. With the
Table 2 Validation results of the GVAP
Method Parameter N GVAP (r values) p level
GlyCulator CONGA 14 1 p < 0.001
MODD 14 1 p < 0.001
Medtronic® Avg. AUC-H 14 1 p < 0.001
PATR 14 0.995 p < 0.001
Avg. AUC-L 14 0.999 p < 0.001
PBTR 14 0.992 p < 0.001
Manual MAGE avg. 20 0.997 p < 0.001
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episodes. On the basis of CGM results, continuous feeding regime was introduced,
resulting in significantly decreased variability metrics of the glucose curve (Figure 5). In
the above case the CONGA seemed to be the most representative parameter that eval-
uated the glucose difference hour by hour, being sensitive for the short term variability.
Its value decreased from 74 to 20 mg/dL after adjustment of treatment as rapid excur-
sions were significantly reduced. Furthermore, in a group of 21 PICU patients we have
found significant correlation of the mortality outcome index PRISM III and of MAGE
avg. (r = 0,55; p < 0.05, unpublished observation by our group).
Discussion
The last decade emerged an expanding interest on glucose homeostasis disorders in pa-
tients needing intensive care. Recently, glucose variability has been pointed out to play
a significant role in intensive care morbidity and mortality [12,13]. However, there has
been lack of evidence of which variability parameters could best characterize the sever-
ity of illness. The demand for more accurate clinical follow up (incorporating more fre-
quent glucose sampling) has led to the introduction of several glucose variability
parameters. The CONGA and MODD were usually derived from CGM measurement,
while others such as Avg. AUC, MAGE, PATR/PBTR, SD and glycemic lability index
(GLI) not. Initially for research purposes, then for clinical monitoring it is essential to
create a complex tool of parameters that could be analyzed by a suitable program. Our
aim in the present study was to unify the most commonly used parameters of glucose
variability in a freely accessible application. Prior to further research practices or intro-
duction to clinical use, we felt it necessary to describe the development process and
publish the first pilot test results.
In 2001 Van den Berghe demonstrated that tight glycemic control (TGC) reduced
mortality in critically ill cardiac surgical patients, however, subsequent investigations
did not confirm this benefit consequently [17-19]. The major disadvantage of TGC is
the more frequent occurrence of hypoglycemia, nevertheless, TGC, based on STAR-
Liege or SPRINT protocol could diminish the prevalence of hypoglycemic episodes
[20,21]. In the future the routine use of CGM with sophisticated glucose-insulin algo-
rithms might contribute to safer implementation of TGC among critically ill pediatric
and adult patients. However, further research is needed to identify more factors, which
can potentially contribute to the elevated glucose variability. CONGA refers mainly
to the within day variability, while MODD reflects on the interday variability. MAGE,
Avg. AUC-H/L and PATR/PBTR provide general interpretation on the glycemic
Table 3 Descriptive statistics on the accuracy of the GVAP
Reference Difference (Reference-GVAP )
N Max. Min. Mean SD Max. Min. Mean SD Outliers
CONGA (mg/dL) 14 43 9 20.4 11.6 0.7 -0.1 0.1 0.2 1
MODD (mg/dL) 14 90.7 11.3 29.5 20.7 1.7 -0.5 0.2 0.5 1
Avg. AUC-H (mg/dL) 14 27.5 0 3.4 7.6 0.4 0 0 0.1 1
PATR (%) 14 48.5 0 8.8 14.2 0 -1.6 -0.5 0.6 0
Avg. AUC-L (mg/dL) 14 3.3 0 1.3 1.8 0.1 0 0 0.1 0
PBTR (%) 14 24.5 0 14 15 1.9 -0.2 0.3 0.6 1
MAGE avg. (mg/dL) 20 128.3 0 78.9 33.1 9.3 -5.1 0.2 2.4 2
Difference: difference of the reference measurement and GVAP, Outliers: number of points out of 2 SD. Time of the
observation was 48 hours.
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the most common critical care diagnostic or therapeutic procedures [e.g. bronchoscopy,
necrectomy in burned patients, epidural analgesia] affect the short term glucose vari-
ability (CONGA); (2) how do the perioperative fluid and feeding management influence
the MODD, (3) what common pitfalls of the different intravenous insulin protocols can
be justified (MAGE, Avg. AUC-H/L, PATR, PBTR).
On comparison of our program with two existing programs for glucose variability
analysis we have found a good correlation between the results of all tested parameters.
Literature data varies slightly with regards to MAGE definitions and programming of
MAGE calculation. Therefore, we applied manual calculation based on Baghurst’s def-
inition and not compared GVAP with the MAGE calculations of GlyCulator.
Agreement between the reference programs and GVAP was investigated with Pear-
son, Spearman correlation and Bland-Altman analysis. We have found strong correl-
ation, but outliers were identified in 5 variables. In the MAGE avg. group we observedFigure 4 Bland-Altman plot. Average glucose concentration versus MAGE (Manual) – MAGE (GVAP)
glucose difference.
Figure 5 Sample days of a patient with dumping syndrome. A, during conventional feeding the patient
presented severe hypoglycemic episodes. B, after introduction of continuous enteral feeding the glycemic
variability parameters and severity of hypoglycemia reduced. The sample curves represent a 24-hours long
period; the dots are the calibration points.
Marics et al. BioMedical Engineering OnLine  (2015) 14:37 Page 10 of 13two considerable alterations (9,3 and 5,1 mg/dL) between GVAP and manual calcula-
tion, as reference, due to error of manual calculation (Figure 4). It seemed that the ana-
lysis of high variability recordings were more reliable and simple with GVAP, compared
to the traditional manual way. As for the other variables outliers were not clinically signifi-
cant despite of the statistical difference. Possible explanations for the differences were data
loss at unit conversion (mmol/L to mg/dL), missing values, or linear interpolation.
It should not be ignored that both the interpolation and the calibration may have sig-
nificant effect on glucose variability. In case of missing data the linear interpolation can
falsely decrease the variability as a result of the filling process of the unknown points.
The calibration is the other crucial point. For example, if there is a 50 mg/dL difference
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sor evaluates the calibration value and the parallel subcutaneous glucose concentration,
then corrects the actual subcutaneous concentration. In this theoretical case it may
cause a sudden step in the subcutaneous glucose curve, resulting in falsely elevated glu-
cose variability. These phenomenon unfortunately accompany CGM measurements,
however, their frequency could be reduced by more frequent calibration [22]. In view of
the above, in clinical trials the researchers should calculate the general accuracy of the
CGM with Pearson correlation, Clarke’s error grid and Bland-Altman analysis. More-
over, the number of interpolated data should also be added. GVAP gives the total num-
ber of glucose concentrations and the numbers of interpolated data (Figure 3). In one
section up to 21 glucose values can be interpolated.
Several advantages of the program designed by us can be highlighted. The adjustable
threshold can be useful in the investigation of various clinical questions; on the other
hand the graphical representation of the glucose curves can help the interpretation of
the variability parameters. Minor limitations can also be spotted: GLI was not taken
into account during the developing process, GVAP does not give any information about
the accuracy of the CGM measurement, and the installation of MATLAB software is
required for running of GVAP.
Conclusions
Our program provides a user-friendly option for researchers who require detailed ana-
lysis of the continuous glucose monitoring glucose curve. In the future, this application
may help to present more detailed information on glucose homeostasis disorders of pa-
tients in the intensive care setting.
Additional files
Additional file 1: Contains the full source code of the GVAP (GlyVar_Script.zip - http://sourceforge.net/
projects/glyvariab/files/?source=navbar).
Additional file 2: Contains the user documentation (User documentation for GVAP.doc - http://sourceforge.net/
projects/glyvariab/files/?source=navbar).
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